EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
Several reviews and guidelines on the management of mycosis fungoides and Sézary syndrome (MF/SS) have been published; however, treatment strategies for patients with MF/SS vary from institution to institution and no European consensus has yet been established. There are few phase III trials to support treatment decisions for MF/SS and treatment is often determined by institutional experience. In order to summarise the available evidence and review 'best practices' from each national group, the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force met in September 2004 to establish European guidelines for the treatment of MF/SS. This article reviews the treatment regimens selected for inclusion in the guidelines and summarises the clinical data for treatments appropriate for each stage of MF/SS. Guideline recommendations are presented according to the quality of supporting data, as defined by the Oxford Centre for Evidence-Based Medicine. Skin-directed therapies are the most appropriate option for early-stage MF/SS and most patients can look forward to a normal life expectancy. Patients with advanced disease should be encouraged to participate in clinical trials and maintenance of quality of life should be paramount.
Trautinger
Franz
F
Division of Special and Environmental Dermatology, Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria.
Knobler
Robert
R
Willemze
Rein
R
Peris
Ketty
K
Stadler
Rudolph
R
Laroche
Liliane
L
D'Incan
Michel
M
Ranki
Annamari
A
Pimpinelli
Nicola
N
Ortiz-Romero
Pablo
P
Dummer
Reinhard
R
Estrach
Teresa
T
Whittaker
Sean
S
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009182:Mycosis Fungoides / Q000145:classification / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D010789:Phototherapy / Q000379:methods; D017410:Practice Guidelines as Topic; D012751:Sezary Syndrome / Q000145:classification / Q000473:pathology / Q000628:therapy*; D012878:Skin Neoplasms / Q000145:classification / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents